A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2002
10/17/2002	WO2002081754A1 Nucleic acid vaccines for prevention of flavivirus infection
10/17/2002	WO2002081741A2 Use of products of genes of the 2'-5' oligoadenylate synthetase family (oas) for screening antiviral agents and for detecting responsiveness to flaviviridae infection
10/17/2002	WO2002081728A2 Quinoline inhibitors of hyak1 and hyak3 kinases
10/17/2002	WO2002081709A2 Modified hpv e6 and e7 genes and proteins useful for vaccination
10/17/2002	WO2002081646A2 Epitope sequences
10/17/2002	WO2002081621A2 Vaccine against the nile fever virus
10/17/2002	WO2002081519A2 Ifn-thy fusion protein,dna coding therefore,its preparation and application
10/17/2002	WO2002081504A2 Multimerization of hiv-1 vif protein as a therapeutic target
10/17/2002	WO2002081499A2 Somatostatin agonists
10/17/2002	WO2002081494A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	WO2002081493A1 9-amino-14-membered macrolide derived from leucomycin
10/17/2002	WO2002081487A1 Low concentration rates
10/17/2002	WO2002081483A2 Inhibitors of acyl glucosaminyl inositol amidase and methods of use
10/17/2002	WO2002081478A2 Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
10/17/2002	WO2002081475A1 Jun kinase inhibitors
10/17/2002	WO2002081470A1 Oxazolidinones containing a sulfonimid group as antibiotics
10/17/2002	WO2002081468A1 Oxazolidinones and their use as antibacterial agents
10/17/2002	WO2002081456A1 Cyanamide, alkoxyamino, and urea derivatives of 4, 4-disubstituted-3, 4-dihydro-2 (1h)- quinazolinones as hiv reverse transcriptase inhibitors
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081441A1 Process for the preparation of substituted pyrrolidine neuraminidase inhibitors
10/17/2002	WO2002081426A1 Peptide deformylase inhibitors
10/17/2002	WO2002080982A2 Nucleic acid mucosal immunization
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080976A2 Hsa-free formulations of interferon-beta
10/17/2002	WO2002080966A2 Method for producing a vaccine containing autologous antibodies
10/17/2002	WO2002080965A2 Vaccine composition
10/17/2002	WO2002080964A1 Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid
10/17/2002	WO2002080958A1 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
10/17/2002	WO2002080956A2 Use of compounds modulating rxr-ppar heterodimer activity as medicine for treating hepatitis c
10/17/2002	WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002	WO2002080940A2 Pharmacologically active strong acid solutions
10/17/2002	WO2002080939A2 Ionene polymers and their use as antimicrobial agents
10/17/2002	WO2002080938A1 Use of sodium nucleospermate for treating aids and treatment method
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080923A1 Substances for use in therapy of diseases that are caused by highly proliferative cells
10/17/2002	WO2002080921A1 Composition for inhibiting hiv activity extracted from paecilomyces sp. (tochu-kaso) j300
10/17/2002	WO2002080914A2 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	WO2002080911A2 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
10/17/2002	WO2002080901A2 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002080883A2 Method and composition for solubilising a biologically active compound with low water solubility
10/17/2002	WO2002080856A2 Triaza compound immunoregulatory agents
10/17/2002	WO2002080851A2 Chimeric vaccines
10/17/2002	WO2002080841A2 Antibacterial oxazolidinones with a cyclic sulphilimine or sulphoximine
10/17/2002	WO2002080840A2 Immunity adjuvant containing a complexed metal cation and vaccine containing same
10/17/2002	WO2002080678A1 Antifungal composition with enhanced bioavailability
10/17/2002	WO2002080668A2 Antimicrobial formulations
10/17/2002	WO2002080648A2 Mucosal boosting following parenteral priming
10/17/2002	WO2002060924A3 Identification and applications of porcine reproductive and respiratory syndrome virus host susceptibility factor(s) for improved swine breeding and development of a non-simian recombinant cell line for propagation of the virus and a target for a novel class of antiviral compounds
10/17/2002	WO2002050081A3 Antimicrobial agents
10/17/2002	WO2002043699A3 Preparation of large liposomes by infusion into peg
10/17/2002	WO2002043567A3 A method of treating cancer
10/17/2002	WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002	WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002	WO2002036733A9 Cd36 as a heat shock protein receptor and uses thereof
10/17/2002	WO2002036605A9 Estrone-derivatives having cytoprotective activity
10/17/2002	WO2002036146A3 Epitope-beta microglobulin polynucleotide for anti-cancer immunotherapy
10/17/2002	WO2002036108A3 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases
10/17/2002	WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002	WO2002029061A3 G-protein coupled receptors
10/17/2002	WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002	WO2002010192A9 Somatostatin analogues
10/17/2002	WO2002008420A3 A method of down-regulating gene expression
10/17/2002	WO2001098323A3 G-protein coupled receptors
10/17/2002	WO2001096283A9 Hiv integrase inhibitors
10/17/2002	WO2001060847A9 Avirulent, immunogenic flavivirus chimeras
10/17/2002	WO2001058241A9 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
10/17/2002	WO2001053330A9 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
10/17/2002	WO2001049279A3 Use of steroidal alkaloids to reverse multidrug resistance
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	WO2001040497A3 Method for obtaining nucleic acids from an environment sample
10/17/2002	US20020152498 Mutant plant
10/17/2002	US20020152481 Genetic engineering; qualitative analysis
10/17/2002	US20020151715 Imidazole derivatives
10/17/2002	US20020151679 Peptide for use in the treatment of infections, viral and cancer diseases
10/17/2002	US20020151677 Replikins and methods of identifying replikin-containing sequences
10/17/2002	US20020151676 Streptogramin derivatives, preparation method and compositions containing same
10/17/2002	US20020151599 Formulations having an antiviral action
10/17/2002	US20020151586 Antidiabetic agents
10/17/2002	US20020151584 Salvia plant extracts; ester benzofuran derivatives
10/17/2002	US20020151577 Antiparasitic composition for the treatment and protection of pets
10/17/2002	US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors
10/17/2002	US20020151571 Activity against arthropods in agriculture and parasites encountered in animal husbandry
10/17/2002	US20020151560 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/17/2002	US20020151553 Such as 4-(4-chlorophenyl)1-(3-(5-cyano-5H-dibenzo(a,d) cycloheptene-5-yl)propyl)piperidin-4-ol for treatment of diseases associated with aberrant leukocyte recruitment and/or activation
10/17/2002	US20020151546 HIV protease inhibitors based on amino acid derivatives
10/17/2002	US20020151518 Oligonucleotide mediated specific sytokine induction and reduction of tumor growth in a mammal
10/17/2002	US20020151512 Used to diagnose or treat cancer, restenosis, a disease caused by a virus, a disease affected by integrins or cell-cell adhesion receptor or a disease triggered by diffusible factors
10/17/2002	US20020151510 Methods and compositions for the treatment of human immunodeficiency virus infection
10/17/2002	US20020151505 Treatment of helicobacter with isothiocyanates
10/17/2002	US20020151488 G-CSF analog compositions and methods
10/17/2002	US20020151484 SID nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof
10/17/2002	US20020151476 An isolated and purified antiviral protein or peptide from Nostoc ellipsosporum; viricides; coupled to an effector molecule; inhibits replication of a virus, e.g. a retrovirus, in particular a human immunodeficiency virus, HIV
10/17/2002	US20020151474 Processes for making pharmaceutical oral ECB formulations and compositions
10/17/2002	US20020151049 Self-enhancing, pharmacologically controllable expression systems
10/17/2002	US20020151022 Kinase capable of site-specific phosphorylation of IkappaBalpha
10/17/2002	US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002	US20020150977 Nucleotide sequences coding protein for use in the diagnosis, treatment and prevention of autoimmune, cell proliferative and inflammatory diseases
10/17/2002	US20020150963 Map
10/17/2002	US20020150888 Methods of screening for modulators of HIV infection

1 ... 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 ... 1798